{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:26:07Z","timestamp":1791134767811,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2013.355","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T17:11:59Z","timestamp":1380820319000},"page":"e817-e817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity"],"prefix":"10.1038","volume":"4","author":[{"given":"I","family":"Rubera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Duranton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cougnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Mograbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tauc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"BFcddis2013355_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307\u2013320.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcddis2013355_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","volume":"61","author":"V Launay-Vacher","year":"2008","unstructured":"Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M . Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008; 61: 903\u2013909.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcddis2013355_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z . Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994\u20131007.","journal-title":"Kidney Int"},{"key":"BFcddis2013355_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3109\/10408444.2011.602662","volume":"41","author":"PD Sanchez-Gonzalez","year":"2011","unstructured":"Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI . An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 2011; 41: 803\u2013821.","journal-title":"Crit Rev Toxicol"},{"key":"BFcddis2013355_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","volume":"167","author":"G Ciarimboli","year":"2005","unstructured":"Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167: 1477\u20131484.","journal-title":"Am J Pathol"},{"key":"BFcddis2013355_CR6","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1152\/ajprenal.90545.2008","volume":"296","author":"N Pabla","year":"2009","unstructured":"Pabla N, Murphy RF, Liu K, Dong Z . The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296: F505\u2013F511.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFcddis2013355_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","volume":"176","author":"G Ciarimboli","year":"2010","unstructured":"Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010; 176: 1169\u20131180.","journal-title":"Am J Pathol"},{"issue":"4 Pt 2","key":"BFcddis2013355_CR8","first-page":"F700","volume":"270","author":"W Lieberthal","year":"1996","unstructured":"Lieberthal W, Triaca V, Levine J . Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 1996; 270 (4 Pt 2): F700\u2013F708.","journal-title":"Am J Physiol"},{"key":"BFcddis2013355_CR9","first-page":"47","volume":"1","author":"MH Hanigan","year":"2003","unstructured":"Hanigan MH, Devarajan P . Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 2003; 1: 47\u201361.","journal-title":"Cancer Ther"},{"key":"BFcddis2013355_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00280-007-0459-y","volume":"61","author":"NA Santos","year":"2008","unstructured":"Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC . Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008; 61: 145\u2013155.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcddis2013355_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00204-007-0262-x","volume":"82","author":"CL Do Amaral","year":"2008","unstructured":"Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM et al. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 2008; 82: 363\u2013370.","journal-title":"Arch Toxicol"},{"key":"BFcddis2013355_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000262453","volume":"55","author":"S Saleh","year":"2009","unstructured":"Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM . Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009; 55: 399\u2013406.","journal-title":"Chemotherapy"},{"key":"BFcddis2013355_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.etp.2008.09.003","volume":"61","author":"YI Chirino","year":"2009","unstructured":"Chirino YI, Pedraza-Chaverri J . Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61: 223\u2013242.","journal-title":"Exp Toxicol Pathol"},{"key":"BFcddis2013355_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1681\/ASN.2006030269","volume":"18","author":"F Jouret","year":"2007","unstructured":"Jouret F, Bernard A, Hermans C, Dom G, Terryn S, Leal T et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 2007; 18: 707\u2013718.","journal-title":"J Am Soc Nephrol"},{"key":"BFcddis2013355_CR15","doi-asserted-by":"publisher","first-page":"F796","DOI":"10.1152\/ajprenal.00237.2002","volume":"284","author":"H Barriere","year":"2003","unstructured":"Barriere H, Belfodil R, Rubera I, Tauc M, Poujeol C, Bidet M et al. CFTR null mutation altered cAMP-sensitive and swelling-activated Cl- currents in primary cultures of mouse nephron. Am J Physiol Renal Physiol 2003; 284: F796\u2013F811.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFcddis2013355_CR16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.06.017","volume":"181","author":"C Duranton","year":"2012","unstructured":"Duranton C, Rubera I, Cougnon M, Melis N, Chargui A, Mograbi B et al. CFTR is involved in the fine tuning of intracellular redox status: physiological implications in cystic fibrosis. Am J Pathol 2012; 181: 1367\u20131377.","journal-title":"Am J Pathol"},{"key":"BFcddis2013355_CR17","doi-asserted-by":"publisher","first-page":"F435","DOI":"10.1152\/ajprenal.00286.2009","volume":"298","author":"S l'Hoste","year":"2010","unstructured":"l'Hoste S, Chargui A, Belfodil R, Corcelle E, Duranton C, Rubera I et al. CFTR mediates apoptotic volume decrease and cell death by controlling glutathione efflux and ROS production in cultured mice proximal tubules. Am J Physiol Renal Physiol 2010; 298: F435\u2013F453.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFcddis2013355_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.freeradbiomed.2008.12.009","volume":"46","author":"S L'Hoste","year":"2009","unstructured":"L'Hoste S, Chargui A, Belfodil R, Duranton C, Rubera I, Mograbi B et al. CFTR mediates cadmium-induced apoptosis through modulation of ROS level in mouse proximal tubule cells. Free Radic Biol Med 2009; 46: 1017\u20131031.","journal-title":"Free Radic Biol Med"},{"key":"BFcddis2013355_CR19","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI0216112","volume":"110","author":"T Ma","year":"2002","unstructured":"Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651\u20131658.","journal-title":"J Clin Invest"},{"key":"BFcddis2013355_CR20","doi-asserted-by":"publisher","first-page":"C810","DOI":"10.1152\/ajpcell.2001.281.3.C810","volume":"281","author":"H Barriere","year":"2001","unstructured":"Barriere H, Poujeol C, Tauc M, Blasi JM, Counillon L, Poujeol P . CFTR modulates programmed cell death by decreasing intracellular pH in Chinese hamster lung fibroblasts. Am J Physiol Cell Physiol 2001; 281: C810\u2013C824.","journal-title":"Am J Physiol Cell Physiol"},{"key":"BFcddis2013355_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkl051","volume":"34","author":"B Liedert","year":"2006","unstructured":"Liedert B, Pluim D, Schellens J, Thomale J . Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 2006; 34: e47.","journal-title":"Nucleic Acids Res"},{"key":"BFcddis2013355_CR22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/ndt\/17.11.1890","volume":"17","author":"C Bazzi","year":"2002","unstructured":"Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890\u20131896.","journal-title":"Nephrol Dial Transplant"},{"key":"BFcddis2013355_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000078452","volume":"24","author":"J Mishra","year":"2004","unstructured":"Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P . Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307\u2013315.","journal-title":"Am J Nephrol"},{"key":"BFcddis2013355_CR24","doi-asserted-by":"publisher","first-page":"F543","DOI":"10.1152\/ajprenal.00112.2004","volume":"287","author":"I Arany","year":"2004","unstructured":"Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL . Cisplatin-induced cell death is EGFR\/src\/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 2004; 287: F543\u2013F549.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFcddis2013355_CR25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.bcp.2007.01.010","volume":"73","author":"M Jiang","year":"2007","unstructured":"Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T et al. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 2007; 73: 1499\u20131510.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2013355_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ki.2012.64","volume":"82","author":"J Kim","year":"2012","unstructured":"Kim J, Long KE, Tang K, Padanilam BJ . Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity. Kidney Int 2012; 82: 193\u2013203.","journal-title":"Kidney Int"},{"key":"BFcddis2013355_CR27","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1172\/JCI45586","volume":"121","author":"N Pabla","year":"2011","unstructured":"Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO et al. Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 2011; 121: 2709\u20132722.","journal-title":"J Clin Invest"},{"key":"BFcddis2013355_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.bbapap.2008.12.004","volume":"1794","author":"MA Seeger","year":"2009","unstructured":"Seeger MA, van Veen HW . Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 2009; 1794: 725\u2013737.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2013355_CR29","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1248\/bpb.33.1867","volume":"33","author":"H Katsuda","year":"2010","unstructured":"Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 2010; 33: 1867\u20131871.","journal-title":"Biol Pharm Bull"},{"key":"BFcddis2013355_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jps.20228","volume":"94","author":"ND Sonawane","year":"2005","unstructured":"Sonawane ND, Muanprasat C, Nagatani R Jr., Song Y, Verkman AS . In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J Pharm Sci 2005; 94: 134\u2013143.","journal-title":"J Pharm Sci"},{"key":"BFcddis2013355_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1053\/j.gastro.2003.11.005","volume":"126","author":"JR Thiagarajah","year":"2004","unstructured":"Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS . Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004; 126: 511\u2013519.","journal-title":"Gastroenterology"},{"key":"BFcddis2013355_CR32","doi-asserted-by":"publisher","first-page":"L936","DOI":"10.1152\/ajplung.00354.2003","volume":"287","author":"DB Salinas","year":"2004","unstructured":"Salinas DB, Pedemonte N, Muanprasat C, Finkbeiner WF, Nielson DW, Verkman AS . CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor. Am J Physiol Lung Cell Mol Physiol 2004; 287: L936\u2013L943.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"BFcddis2013355_CR33","doi-asserted-by":"publisher","first-page":"G753","DOI":"10.1152\/ajpgi.00130.2005","volume":"289","author":"Y Akiba","year":"2005","unstructured":"Akiba Y, Jung M, Ouk S, Kaunitz JD . A novel small molecule CFTR inhibitor attenuates HCO3- secretion and duodenal ulcer formation in rats. Am J Physiol Gastrointest Liver Physiol 2005; 289: G753\u2013G759.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"BFcddis2013355_CR34","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1021\/jm200505e","volume":"54","author":"DS Snyder","year":"2011","unstructured":"Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS . Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem 2011; 54: 5468\u20135477.","journal-title":"J Med Chem"},{"key":"BFcddis2013355_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2012.199","volume":"82","author":"B Humanes","year":"2012","unstructured":"Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, Blanco-Codesido M et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 2012; 82: 652\u2013663.","journal-title":"Kidney Int"},{"key":"BFcddis2013355_CR36","doi-asserted-by":"publisher","first-page":"11294","DOI":"10.1073\/pnas.1203129109","volume":"109","author":"P Sengupta","year":"2012","unstructured":"Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci USA 2012; 109: 11294\u201311299.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2013355_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/sj.embor.7400035","volume":"5","author":"J Lacroix","year":"2004","unstructured":"Lacroix J, Poet M, Maehrel C, Counillon L . A mechanism for the activation of the Na\/H exchanger NHE-1 by cytoplasmic acidification and mitogens. EMBO Rep 2004; 5: 91\u201396.","journal-title":"EMBO Rep"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis2013355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis2013355","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2013355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:55:53Z","timestamp":1672962953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2013355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["BFcddis2013355"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2013.355","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]},"assertion":[{"value":"20 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}